Professional Role and Responsibilities
Lily Li serves as the Medical Safety Officer and Senior Director, Medical, Scientific & Clinical Affairs at QuidelOrtho, a globally recognized leader in in-vitro diagnostics. In this leadership role, she is primarily responsible for evaluating potential medical risks and guiding risk mitigation strategies associated with QuidelOrtho’s diagnostic products and technologies. Her position encompasses cross-functional oversight within medical affairs, ensuring scientific rigor and clinical validity of the company's diagnostics, with a focus on patient safety and regulatory compliance.
Her portfolio involves critical areas such as patient blood management, transfusion reactions, platelet storage and utilization, emphasizing the role of multidisciplinary collaboration among medical laboratory technologists and healthcare professionals. She contributes to the interpretation and communication of diagnostic testing data to improve patient outcomes.
QuidelOrtho specifically cites her involvement in innovative solutions such as the recent development and launch of a Fentanyl test on Vitros® Systems, addressing emergent clinical needs for enhanced opioid testing in emergency and hospital settings. This underscores her active engagement in advancing QuidelOrtho’s assay portfolio aligned with public health priorities.
Educational Background
- Doctor of Medicine (MD) from Beijing Medical University (Peking University)
- Doctor of Philosophy (PhD) in Immunology from the University of Alberta (1991)
- Master of Business Administration (MBA) from Temple University (2008)
This multidisciplinary education integrates clinical expertise with deep scientific research training and business acumen, positioning Dr. Li to effectively bridge clinical, scientific, and commercial aspects of diagnostics.
Career Progression and Prior Experience
Prior to her current role, Dr. Li held several senior leadership positions within QuidelOrtho and affiliated organizations, including:
- Vice President of Marketing
- Senior Vice President of the Molecular Business Unit
She also has a background as a management consultant in life sciences and strategic marketing/business development at companies such as NanoString Technologies and Illumina, reflecting extensive expertise in molecular diagnostics and life science research and development.
Scientific and Industry Contributions
Dr. Li is recognized within the clinical chemistry and in-vitro diagnostics community for her expertise in medical safety and scientific affairs, contributing to improved laboratory medicine and patient care through careful evaluation of diagnostic products’ safety profiles.
She has participated in corporate task forces under the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), advancing the integration of corporate stakeholders’ contributions to the broader clinical chemistry field.
Dr. Li contributes regularly to QuidelOrtho’s educational and scientific outreach initiatives, including a monthly podcast series ("QuidelOrtho Science Bytes") that focuses on laboratory advancements, diagnostic testing innovations (e.g., blood group discovery, diabetes diagnostics), and the critical roles played by medical laboratory technologists in healthcare systems.
Additional public materials indicate her involvement in explaining scientific mechanisms, including the role of neutralizing antibodies to SARS-CoV-2 and the utility of convalescent plasma during the COVID-19 pandemic, illustrating her engagement with infectious disease diagnostics and patient blood management.
Location and Organizational Context
- Based in Exton, Pennsylvania, United States.
- Working from QuidelOrtho’s corporate location at 1001 US RT 202, Raritan, NJ 08869, USA.
QuidelOrtho operates at the forefront of molecular and immunodiagnostics, and her leadership role is pivotal to maintaining the company’s compliance with high standards required by FDA and other regulatory authorities.
Industry Recognition and Personal Attributes
While specific awards or notable individual achievements are not detailed, Dr. Li is acknowledged for being a cross-functional leader committed to advancing healthcare outcomes through innovative research and quality healthcare practice. She emphasizes the importance of teamwork in her professional philosophy.
Her multifaceted credentials (MD, PhD, MBA) and senior leadership tenure underscore her capacity to influence medical safety policies and scientific strategy within a complex, regulated environment. Multiple sources highlight her ability to synthesize scientific rigor and business objectives, critical for driving product safety and clinical relevance.
Key actionable insights for engagement reference her leadership in medical safety and scientific affairs at a company actively expanding its diagnostic assay portfolio to meet emergent clinical needs (e.g., opioid crisis), indicating potential alignment around patient safety priorities, assay innovation, and market-driven scientific communication.
